Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

HIV-1-based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions.

Gonelli CA, Khoury G, Center RJ, Purcell DFJ.

Viruses. 2019 Jun 2;11(6). pii: E507. doi: 10.3390/v11060507.

2.

Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models.

Nguyen W, Jacobson J, Jarman KE, Jousset Sabroux H, Harty L, McMahon J, Lewin SR, Purcell DF, Sleebs BE.

J Med Chem. 2019 May 23;62(10):5148-5175. doi: 10.1021/acs.jmedchem.9b00462. Epub 2019 Apr 29.

PMID:
30973727
3.

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing.

Khoury G, Purcell DFJ.

J Vis Exp. 2019 Jan 22;(143). doi: 10.3791/58753.

PMID:
30735158
4.

HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal.

Moso MA, Anderson JL, Adikari S, Gray LR, Khoury G, Chang JJ, Jacobson JC, Ellett AM, Cheng WJ, Saleh S, Zaunders JJ, Purcell DFJ, Cameron PU, Churchill MJ, Lewin SR, Lu HK.

AIDS. 2019 Feb 1;33(2):199-209. doi: 10.1097/QAD.0000000000002075.

PMID:
30562171
5.

The Molecular Biology of HIV Latency.

Khoury G, Darcis G, Lee MY, Bouchat S, Van Driessche B, Purcell DFJ, Van Lint C.

Adv Exp Med Biol. 2018;1075:187-212. doi: 10.1007/978-981-13-0484-2_8. Review.

PMID:
30030794
6.

HIV latency reversing agents act through Tat post translational modifications.

Khoury G, Mota TM, Li S, Tumpach C, Lee MY, Jacobson J, Harty L, Anderson JL, Lewin SR, Purcell DFJ.

Retrovirology. 2018 May 11;15(1):36. doi: 10.1186/s12977-018-0421-6.

7.

Identification of Native and Posttranslationally Modified HLA-B*57:01-Restricted HIV Envelope Derived Epitopes Using Immunoproteomics.

Ramarathinam SH, Gras S, Alcantara S, Yeung AWS, Mifsud NA, Sonza S, Illing PT, Glaros EN, Center RJ, Thomas SR, Kent SJ, Ternette N, Purcell DFJ, Rossjohn J, Purcell AW.

Proteomics. 2018 Jun;18(12):e1700253. doi: 10.1002/pmic.201700253. Epub 2018 Apr 10.

PMID:
29437277
8.

Regulation of H3K4me3 at Transcriptional Enhancers Characterizes Acquisition of Virus-Specific CD8+ T Cell-Lineage-Specific Function.

Russ BE, Olshansky M, Li J, Nguyen MLT, Gearing LJ, Nguyen THO, Olson MR, McQuilton HA, Nüssing S, Khoury G, Purcell DFJ, Hertzog PJ, Rao S, Turner SJ.

Cell Rep. 2017 Dec 19;21(12):3624-3636. doi: 10.1016/j.celrep.2017.11.097.

9.

No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.

Mota TM, Rasmussen TA, Rhodes A, Tennakoon S, Dantanarayana A, Wightman F, Hagenauer M, Roney J, Spelman T, Purcell DFJ, McMahon J, Hoy JF, Prince HM, Elliott JH, Lewin SR.

AIDS. 2017 May 15;31(8):1137-1141. doi: 10.1097/QAD.0000000000001442.

10.

Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response.

Heydarchi B, Center RJ, Gonelli C, Muller B, Mackenzie C, Khoury G, Lichtfuss M, Rawlin G, Purcell DF.

PLoS One. 2016 Jun 14;11(6):e0157353. doi: 10.1371/journal.pone.0157353. eCollection 2016.

11.

Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells.

Gray LR, On H, Roberts E, Lu HK, Moso MA, Raison JA, Papaioannou C, Cheng WJ, Ellett AM, Jacobson JC, Purcell DF, Wesselingh SL, Gorry PR, Lewin SR, Churchill MJ.

J Neurovirol. 2016 Aug;22(4):455-63. doi: 10.1007/s13365-015-0413-4. Epub 2016 Jan 4.

PMID:
26727904
12.

Endogenous Murine BST-2/Tetherin Is Not a Major Restriction Factor of Influenza A Virus Infection.

Londrigan SL, Tate MD, Job ER, Moffat JM, Wakim LM, Gonelli CA, Purcell DF, Brooks AG, Villadangos JA, Reading PC, Mintern JD.

PLoS One. 2015 Nov 13;10(11):e0142925. doi: 10.1371/journal.pone.0142925. eCollection 2015.

13.

Suppression subtractive hybridization method for the identification of a new strain of murine hepatitis virus from xenografted SCID mice.

Islam MM, Toohey B, Purcell DF, Kannourakis G.

Arch Virol. 2015 Dec;160(12):2945-55. doi: 10.1007/s00705-015-2592-y. Epub 2015 Sep 8.

14.

MYB elongation is regulated by the nucleic acid binding of NFκB p50 to the intronic stem-loop region.

Pereira LA, Hugo HJ, Malaterre J, Huiling X, Sonza S, Cures A, Purcell DF, Ramsland PA, Gerondakis S, Gonda TJ, Ramsay RG.

PLoS One. 2015 Apr 8;10(4):e0122919. doi: 10.1371/journal.pone.0122919. eCollection 2015.

15.

Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium.

Purcell DF, Elliott JH, Ross AL, Frater J.

Retrovirology. 2013 Nov 13;10:134. doi: 10.1186/1742-4690-10-134. Review.

16.

Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection.

Jakobsen MR, Cashin K, Roche M, Sterjovski J, Ellett A, Borm K, Flynn J, Erikstrup C, Gouillou M, Gray LR, Saksena NK, Wang B, Purcell DF, Kallestrup P, Zinyama-Gutsire R, Gomo E, Ullum H, Ostergaard L, Lee B, Ramsland PA, Churchill MJ, Gorry PR.

PLoS One. 2013 Jun 18;8(6):e65950. doi: 10.1371/journal.pone.0065950. Print 2013.

17.

The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.

Flynn JK, Paukovics G, Moore MS, Ellett A, Gray LR, Duncan R, Salimi H, Jubb B, Westby M, Purcell DF, Lewin SR, Lee B, Churchill MJ, Gorry PR, Roche M.

Virology. 2013 Jul 20;442(1):51-8. doi: 10.1016/j.virol.2013.03.026. Epub 2013 Apr 17.

18.

Utility of the Sindbis replicon system as an Env-targeted HIV vaccine.

Center RJ, Miller A, Wheatley AK, Campbell SM, Siebentritt C, Purcell DF.

Vaccine. 2013 Apr 26;31(18):2260-6. doi: 10.1016/j.vaccine.2013.02.064. Epub 2013 Mar 13.

PMID:
23499600
19.

Application of a case-control study design to investigate genotypic signatures of HIV-1 transmission.

Mota TM, Murray JM, Center RJ, Purcell DF, McCaw JM.

Retrovirology. 2012 Jun 25;9:54. doi: 10.1186/1742-4690-9-54.

20.

Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG.

Kramski M, Lichtfuss GF, Navis M, Isitman G, Wren L, Rawlin G, Center RJ, Jaworowski A, Kent SJ, Purcell DF.

Eur J Immunol. 2012 Oct;42(10):2771-81. doi: 10.1002/eji.201242469. Epub 2012 Aug 28.

21.

Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.

Kramski M, Center RJ, Wheatley AK, Jacobson JC, Alexander MR, Rawlin G, Purcell DF.

Antimicrob Agents Chemother. 2012 Aug;56(8):4310-9. doi: 10.1128/AAC.00453-12. Epub 2012 Jun 4.

22.

Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific.

Suzuki K, Ishida T, Yamagishi M, Ahlenstiel C, Swaminathan S, Marks K, Murray D, McCartney EM, Beard MR, Alexander M, Purcell DF, Cooper DA, Watanabe T, Kelleher AD.

RNA Biol. 2011 Nov-Dec;8(6):1035-46. doi: 10.4161/rna.8.6.16264. Epub 2011 Nov 1.

23.

Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.

Byakwaga H, Kelly M, Purcell DF, French MA, Amin J, Lewin SR, Haskelberg H, Kelleher AD, Garsia R, Boyd MA, Cooper DA, Emery S; CORAL Study Group.

J Infect Dis. 2011 Nov 15;204(10):1532-40. doi: 10.1093/infdis/jir559. Epub 2011 Sep 19.

PMID:
21930607
24.

Novel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation.

Kramski M, Gaeguta AJ, Lichtfuss GF, Rajasuriar R, Crowe SM, French MA, Lewin SR, Center RJ, Purcell DF.

J Clin Microbiol. 2011 Oct;49(10):3691-3. doi: 10.1128/JCM.01018-11. Epub 2011 Aug 3.

25.

Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles.

Kirkegaard T, Wheatley A, Melchjorsen J, Bahrami S, Pedersen FS, Center RJ, Purcell DF, Ostergaard L, Duch M, Tolstrup M.

Virol J. 2011 Aug 1;8:381. doi: 10.1186/1743-422X-8-381.

26.

Antibody and B-cell responses may control circulating lipopolysaccharide in patients with HIV infection.

Lim A, Amini A, D'Orsogna LJ, Rajasuriar R, Kramski M, Lewin SR, Purcell DF, Price P, French MA.

AIDS. 2011 Jul 17;25(11):1379-83. doi: 10.1097/QAD.0b013e328348a789.

PMID:
21572302
27.

Co-expression of miRNA targeting the expression of PERK, but not PKR, enhances cellular immunity from an HIV-1 Env DNA vaccine.

Wheatley AK, Kramski M, Alexander MR, Toe JG, Center RJ, Purcell DF.

PLoS One. 2011 Mar 25;6(3):e18225. doi: 10.1371/journal.pone.0018225.

28.

Efficient transcription through an intron requires the binding of an Sm-type U1 snRNP with intact stem loop II to the splice donor.

Alexander MR, Wheatley AK, Center RJ, Purcell DF.

Nucleic Acids Res. 2010 May;38(9):3041-53. doi: 10.1093/nar/gkp1224. Epub 2010 Jan 13.

29.

Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection.

Wade J, Sterjovski J, Gray L, Roche M, Chiavaroli L, Ellett A, Jakobsen MR, Cowley D, Pereira Cda F, Saksena N, Wang B, Purcell DF, Karlsson I, Fenyö EM, Churchill M, Gorry PR.

Virology. 2010 Jan 20;396(2):246-55. doi: 10.1016/j.virol.2009.10.029. Epub 2009 Nov 13.

30.

Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.

Center RJ, Wheatley AK, Campbell SM, Gaeguta AJ, Peut V, Alcantara S, Siebentritt C, Kent SJ, Purcell DF.

Vaccine. 2009 Nov 5;27(47):6605-12. doi: 10.1016/j.vaccine.2009.08.016. Epub 2009 Aug 25.

PMID:
19712773
31.

Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission.

Peut V, Campbell S, Gaeguta A, Center RJ, Wilson K, Alcantara S, Fernandez CS, Purcell DF, Kent SJ.

J Virol. 2009 Sep;83(17):8986-92. doi: 10.1128/JVI.00599-09. Epub 2009 Jun 10.

32.

Characterization of the TRBP domain required for dicer interaction and function in RNA interference.

Daniels SM, Melendez-Peña CE, Scarborough RJ, Daher A, Christensen HS, El Far M, Purcell DF, Lainé S, Gatignol A.

BMC Mol Biol. 2009 May 7;10:38. doi: 10.1186/1471-2199-10-38.

33.

Complexity of the inoculum determines the rate of reversion of SIV Gag CD8 T cell mutant virus and outcome of infection.

Loh L, Reece JC, Fernandez CS, Alcantara S, Center R, Howard J, Purcell DF, Balamurali M, Petravic J, Davenport MP, Kent SJ.

PLoS Pathog. 2009 Apr;5(4):e1000378. doi: 10.1371/journal.ppat.1000378. Epub 2009 Apr 10.

34.

Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.

Gray L, Roche M, Churchill MJ, Sterjovski J, Ellett A, Poumbourios P, Sherieff S, Wang B, Saksena N, Purcell DF, Wesselingh S, Cunningham AL, Brew BJ, Gabuzda D, Gorry PR.

J Virol. 2009 Jun;83(11):5430-41. doi: 10.1128/JVI.02648-08. Epub 2009 Mar 25. Erratum in: J Virol. 2009 Aug;83(15):7794. Sheffief, Shameem [corrected to Sherieff, Shameem].

35.

Controlling HIV infection: HIV co-receptor gets the finger.

Kelleher AD, Purcell DF.

Immunol Cell Biol. 2008 Nov-Dec;86(8):641-2. doi: 10.1038/icb.2008.68. Epub 2008 Sep 9. No abstract available.

PMID:
18779839
36.

Sindbis virus vectors elicit hemagglutinin-specific humoral and cellular immune responses and offer a dose-sparing strategy for vaccination.

Miller A, Center RJ, Stambas J, Deliyannis G, Doherty PC, Howard JL, Turner SJ, Purcell DF.

Vaccine. 2008 Oct 16;26(44):5641-8. doi: 10.1016/j.vaccine.2008.07.102. Epub 2008 Aug 28.

PMID:
18761047
37.

Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.

Repits J, Sterjovski J, Badia-Martinez D, Mild M, Gray L, Churchill MJ, Purcell DF, Karlsson A, Albert J, Fenyö EM, Achour A, Gorry PR, Jansson M.

Virology. 2008 Sep 15;379(1):125-34. doi: 10.1016/j.virol.2008.06.014. Epub 2008 Jul 30.

38.

Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression.

Borggren M, Repits J, Kuylenstierna C, Sterjovski J, Churchill MJ, Purcell DF, Karlsson A, Albert J, Gorry PR, Jansson M.

Retrovirology. 2008 Mar 27;5:28. doi: 10.1186/1742-4690-5-28.

39.

HIV-1 infection induces changes in expression of cellular splicing factors that regulate alternative viral splicing and virus production in macrophages.

Dowling D, Nasr-Esfahani S, Tan CH, O'Brien K, Howard JL, Jans DA, Purcell DF, Stoltzfus CM, Sonza S.

Retrovirology. 2008 Feb 4;5:18. doi: 10.1186/1742-4690-5-18.

40.

Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.

Sterjovski J, Churchill MJ, Ellett A, Gray LR, Roche MJ, Dunfee RL, Purcell DF, Saksena N, Wang B, Sonza S, Wesselingh SL, Karlsson I, Fenyo EM, Gabuzda D, Cunningham AL, Gorry PR.

Retrovirology. 2007 Dec 12;4:89.

41.

Amiloride derivatives inhibit coxsackievirus B3 RNA replication.

Harrison DN, Gazina EV, Purcell DF, Anderson DA, Petrou S.

J Virol. 2008 Feb;82(3):1465-73. Epub 2007 Nov 21.

42.

In vitro dimerization of human immunodeficiency virus type 1 (HIV-1) spliced RNAs.

Sinck L, Richer D, Howard J, Alexander M, Purcell DF, Marquet R, Paillart JC.

RNA. 2007 Dec;13(12):2141-50. Epub 2007 Oct 9.

43.

Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for HIV vaccine strategies.

Rollman E, Smith MZ, Brooks AG, Purcell DF, Zuber B, Ramshaw IA, Kent SJ.

J Immunol. 2007 Oct 1;179(7):4571-9.

44.

Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production.

Christensen HS, Daher A, Soye KJ, Frankel LB, Alexander MR, Lainé S, Bannwarth S, Ong CL, Chung SW, Campbell SM, Purcell DF, Gatignol A.

J Virol. 2007 May;81(10):5121-31. Epub 2007 Mar 14.

45.

A minimal uORF within the HIV-1 vpu leader allows efficient translation initiation at the downstream env AUG.

Krummheuer J, Johnson AT, Hauber I, Kammler S, Anderson JL, Hauber J, Purcell DF, Schaal H.

Virology. 2007 Jul 5;363(2):261-71. Epub 2007 Feb 28.

46.
47.

Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes.

Cameron PU, Handley AJ, Baylis DC, Solomon AE, Bernard N, Purcell DF, Lewin SR.

J Virol. 2007 Mar;81(5):2297-306. Epub 2006 Dec 13.

48.
49.

Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues.

Churchill MJ, Gorry PR, Cowley D, Lal L, Sonza S, Purcell DF, Thompson KA, Gabuzda D, McArthur JC, Pardo CA, Wesselingh SL.

J Neurovirol. 2006 Apr;12(2):146-52.

PMID:
16798676
50.

Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele.

Gray L, Churchill MJ, Keane N, Sterjovski J, Ellett AM, Purcell DF, Poumbourios P, Kol C, Wang B, Saksena NK, Wesselingh SL, Price P, French M, Gabuzda D, Gorry PR.

J Virol. 2006 Apr;80(7):3684-91.

Supplemental Content

Loading ...
Support Center